Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
British Journal of Clinical Pharmacology2020Vol. 86(7), pp. 1314–1325
Citations Over TimeTop 10% of 2020 papers
Eric R. Fedyk, Lin‐Pierre Zhao, Annelize Koch, Glennda Smithson, Jose Estevam, Grace Chen, Gëzim Lahu, Stefan Roepcke, Jianchang Lin, Lachy McLean
Abstract
TAK-079 was well tolerated and s.c. administration elicited more durable reductions in plasmablasts and NK cells. This plasmacytolytic profile could be useful for treating disorders caused by plasma or NK cells, malignant counterparts, and/or pathogenic antibodies.
Related Papers
- → Drug tolerability: How much ambiguity can be tolerated? A systematic review of the assessment of tolerability in clinical studies(2021)45 cited
- → Real-World Evaluation of the Tolerability to Onabotulinum Toxin A: The RETO Study(2022)4 cited
- Tolerability of topical antimicrobials in treatment of acne vulgaris.(2014)
- → Place of Voltaren in clinical practice: emphasis on its tolerability(2009)1 cited
- → TOPICAL MEDICINES IN THE TREATMENT OF ALLERGODERMATHOSIS(2017)